Reprogramming the diseased liver: antioxidant-engineered mRNA nanoparticles as microenvironment modulators in MAFLD

Area of Science:

• Biomedical Engineering
• Hepatology
• Immunology

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) is a major risk factor for hepatocellular carcinoma (HCC).
• Oxidative stress in MAFLD impairs immune function, limiting immunotherapy efficacy for liver cancer.
• Current treatments for MAFLD and associated HCC often have limited success due to these challenges.

Purpose of the Study:

• To develop a nanoparticle-based strategy to simultaneously deliver mRNA and mitigate oxidative stress in the liver.
• To investigate the impact of this nanoparticle on hepatic metabolic homeostasis and immune signaling.
• To assess the potential of this approach to enhance responsiveness to immune checkpoint blockade in MAFLD-associated HCC.

Main Methods:

• Engineered vitamin E-incorporated lipid nanoparticles for targeted mRNA delivery to hepatocytes.
• Assessed the nanoparticles' ability to buffer oxidative stress in the hepatic microenvironment.
• Measured the restoration of T-cell protein tyrosine phosphatase activity and suppression of STAT signaling.
• Evaluated improvements in metabolic parameters and inflammatory markers.
• Tested the enhanced response to immune checkpoint blockade therapy.

Main Results:

• The vitamin E nanoparticles successfully delivered mRNA specifically to hepatocytes.
• The strategy effectively buffered oxidative stress and restored T-cell protein tyrosine phosphatase activity.
• Suppression of STAT signaling was observed, leading to improved metabolic homeostasis.
• Reduced inflammatory signaling and enhanced responsiveness to immune checkpoint blockade were demonstrated.
• This approach shows promise for treating MAFLD-driven liver cancer.

Conclusions:

• Rational nanoparticle engineering can address both therapeutic delivery and microenvironmental modulation in MAFLD.
• This vitamin E-based strategy offers a novel approach to combat MAFLD-associated HCC by enhancing immunotherapy.
• Further research into nanoparticle-based interventions holds significant potential for chronic metabolic liver diseases.